Cargando…

The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus

BACKGROUND: The involvement of high mobility group box-1 (HMGB1) in various inflammatory and autoimmune diseases has been documented but clinical trials on the contribution of this pro-inflammatory alarmin in children with juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Bobek, Dubravka, Grčević, Danka, Kovačić, Nataša, Lukić, Ivan Krešimir, Jelušić, Marija
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267139/
https://www.ncbi.nlm.nih.gov/pubmed/25516724
http://dx.doi.org/10.1186/1546-0096-12-50
_version_ 1782349106934448128
author Bobek, Dubravka
Grčević, Danka
Kovačić, Nataša
Lukić, Ivan Krešimir
Jelušić, Marija
author_facet Bobek, Dubravka
Grčević, Danka
Kovačić, Nataša
Lukić, Ivan Krešimir
Jelušić, Marija
author_sort Bobek, Dubravka
collection PubMed
description BACKGROUND: The involvement of high mobility group box-1 (HMGB1) in various inflammatory and autoimmune diseases has been documented but clinical trials on the contribution of this pro-inflammatory alarmin in children with juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) are basically absent. To address the presence of HMGB1 and a soluble receptor for advanced glycation end products (sRAGE) in different subtypes of JIA and additionally in children with SLE, we enrolled a consecutive sample of children harvested peripheral blood as well as synovial fluids (SF) at diagnosis and correlated it with ordinary acute-phase reactants and clinical markers. METHODS: Serum and synovial fluids levels of HMGB1 and sRAGE in total of 144 children (97 with JIA, 19 with SLE and 27 healthy controls) were determined by ELISA. RESULTS: The children with JIA and those with SLE were characterised by significantly higher serum levels of HMGB1 and significantly lower sRAGE levels compared to the healthy controls. A positive correlation between serum HMGB1 and ESR, CRP, α2 globulin was found while serum sRAGE levels were inversely correlated with the same inflammatory markers in children with JIA. Additionally, high level of serum HMGB1 was related to hepatosplenomegaly or serositis in systemic onset JIA. CONCLUSION: The inverse relationship of the HMGB1 and its soluble receptor RAGE in the blood and SF indicates that inflammation triggered by alarmins may play a role in pathogenesis of JIA as well as SLE. HMGB1 may serve as an inflammatory marker and a potential target of biological therapy in these patients. Further studies need to show whether the determination of HMGB1 levels in patients with JIA can be a useful guideline for detecting disease activity.
format Online
Article
Text
id pubmed-4267139
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42671392014-12-17 The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus Bobek, Dubravka Grčević, Danka Kovačić, Nataša Lukić, Ivan Krešimir Jelušić, Marija Pediatr Rheumatol Online J Research BACKGROUND: The involvement of high mobility group box-1 (HMGB1) in various inflammatory and autoimmune diseases has been documented but clinical trials on the contribution of this pro-inflammatory alarmin in children with juvenile idiopathic arthritis (JIA) and systemic lupus erythematosus (SLE) are basically absent. To address the presence of HMGB1 and a soluble receptor for advanced glycation end products (sRAGE) in different subtypes of JIA and additionally in children with SLE, we enrolled a consecutive sample of children harvested peripheral blood as well as synovial fluids (SF) at diagnosis and correlated it with ordinary acute-phase reactants and clinical markers. METHODS: Serum and synovial fluids levels of HMGB1 and sRAGE in total of 144 children (97 with JIA, 19 with SLE and 27 healthy controls) were determined by ELISA. RESULTS: The children with JIA and those with SLE were characterised by significantly higher serum levels of HMGB1 and significantly lower sRAGE levels compared to the healthy controls. A positive correlation between serum HMGB1 and ESR, CRP, α2 globulin was found while serum sRAGE levels were inversely correlated with the same inflammatory markers in children with JIA. Additionally, high level of serum HMGB1 was related to hepatosplenomegaly or serositis in systemic onset JIA. CONCLUSION: The inverse relationship of the HMGB1 and its soluble receptor RAGE in the blood and SF indicates that inflammation triggered by alarmins may play a role in pathogenesis of JIA as well as SLE. HMGB1 may serve as an inflammatory marker and a potential target of biological therapy in these patients. Further studies need to show whether the determination of HMGB1 levels in patients with JIA can be a useful guideline for detecting disease activity. BioMed Central 2014-12-03 /pmc/articles/PMC4267139/ /pubmed/25516724 http://dx.doi.org/10.1186/1546-0096-12-50 Text en © Bobek et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bobek, Dubravka
Grčević, Danka
Kovačić, Nataša
Lukić, Ivan Krešimir
Jelušić, Marija
The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
title The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
title_full The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
title_fullStr The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
title_full_unstemmed The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
title_short The presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
title_sort presence of high mobility group box-1 and soluble receptor for advanced glycation end-products in juvenile idiopathic arthritis and juvenile systemic lupus erythematosus
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4267139/
https://www.ncbi.nlm.nih.gov/pubmed/25516724
http://dx.doi.org/10.1186/1546-0096-12-50
work_keys_str_mv AT bobekdubravka thepresenceofhighmobilitygroupbox1andsolublereceptorforadvancedglycationendproductsinjuvenileidiopathicarthritisandjuvenilesystemiclupuserythematosus
AT grcevicdanka thepresenceofhighmobilitygroupbox1andsolublereceptorforadvancedglycationendproductsinjuvenileidiopathicarthritisandjuvenilesystemiclupuserythematosus
AT kovacicnatasa thepresenceofhighmobilitygroupbox1andsolublereceptorforadvancedglycationendproductsinjuvenileidiopathicarthritisandjuvenilesystemiclupuserythematosus
AT lukicivankresimir thepresenceofhighmobilitygroupbox1andsolublereceptorforadvancedglycationendproductsinjuvenileidiopathicarthritisandjuvenilesystemiclupuserythematosus
AT jelusicmarija thepresenceofhighmobilitygroupbox1andsolublereceptorforadvancedglycationendproductsinjuvenileidiopathicarthritisandjuvenilesystemiclupuserythematosus
AT bobekdubravka presenceofhighmobilitygroupbox1andsolublereceptorforadvancedglycationendproductsinjuvenileidiopathicarthritisandjuvenilesystemiclupuserythematosus
AT grcevicdanka presenceofhighmobilitygroupbox1andsolublereceptorforadvancedglycationendproductsinjuvenileidiopathicarthritisandjuvenilesystemiclupuserythematosus
AT kovacicnatasa presenceofhighmobilitygroupbox1andsolublereceptorforadvancedglycationendproductsinjuvenileidiopathicarthritisandjuvenilesystemiclupuserythematosus
AT lukicivankresimir presenceofhighmobilitygroupbox1andsolublereceptorforadvancedglycationendproductsinjuvenileidiopathicarthritisandjuvenilesystemiclupuserythematosus
AT jelusicmarija presenceofhighmobilitygroupbox1andsolublereceptorforadvancedglycationendproductsinjuvenileidiopathicarthritisandjuvenilesystemiclupuserythematosus